Journal of the National Cancer Institute
Evaluation of the flipped dose NIVO3+IPI1 in patients with advanced unresectable melanoma.
Karl Björkström, Cissi Liu, Anna Fager, Lisa L Liu, Lars Ny, Hildur Helgadottir
Published: 202510.1093/jnci/djaf327
Abstract
Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg (NIVO1+IPI3) was approved for advanced melanoma in 2016. The CheckMate 511 trial demonstrated improved tolerability with the flipped dose, NIVO3+IPI1, but this regimen has not been approved in melanoma by reg…
Preview only. Read the full abstract at the source